Japan’s medicines regulator has approved the first vaccine based on self-assembling RNA, a spin on the mRNA technology used in current shots, which is designed to deliver greater efficacy with a lower ...

When organizers of the 1933 World’s Fair in Chicago wanted a splashy and futuristic way to kick things off on opening night, astronomer Edwin Frost of Yerkes Observatory had an idea: Turn on the ...

View source version on businesswire.com: https://www.businesswire.com/news/home/20260507780817/en/ The articles, information, and content displayed on this webpage ...

The last time I spoke about Arcturus Therapeutics Holdings Inc. (ARCT) it was with a Seeking Alpha article entitled "Arcturus: LUNAR-CF For CF Presses On With 1st Half Of 2025 Interim Data." Regarding ...

In the preceding three months, 4 analysts have released ratings for Arcturus Therapeutics (NASDAQ:ARCT), presenting a wide array of perspectives from bullish to bearish. In the table below, you'll ...

The company expects to initiate the 12-week Phase II ARCT-032 study in the first half of 2026, enrolling up to 20 participants and focusing on safety and early signs of clinical benefit. For ARCT-810, ...

Arcturus missed both EPS and revenue forecasts significantly. Stock price declined by 5.27% following the earnings report. Revenue declines were attributed to reduced collaboration income. The company ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

View source version on businesswire.com: https://www.businesswire.com/news/home/20251110988919/en/ Arcturus Therapeutics Public Relations & Investor Relations Neda ...

Newly released findings have sent Arcturus Therapeutics’ stock crashing, falling 55% from $23.16 per share to $10.44 per share. (franckreporter/ iStock/Getty Images Plus) In a mixed interim data drop, ...